רשימת מקורות

  1. Gerotziafas GT, Samama MM. Prophylaxis of venous thromboembolism medical patients. CurrOpin PulmMed. 2004; 10:356-365.
  2. American Public Health Association. Presented at: Public Health Leadership Conference on Deep-Vein Thrombosis: February 26, 2003: Washington, D.C. White Paper.
  3. National, Heart, Lung and Blood Institute. How Is Deep Vein Thrombosis Diagnosed? Available at http://www.nhlbi.nih.gov/health/dci/Diseases/Dvt/DVT_Diagnosis.html (accessed September 15, 2009).
  4. American Academy of Orthopaedic Surgeons (June 2001). Deep Vein Thrombosis. Retrieved August 24, 2007, from the American Academy of Orthopaedic Surgeons Web site: http://orthoinfo.aaos.org/fact/thr_report.cfm?Thread_ID=264 .
  5.  Heit et al. Am Soc Hematol. Presented a: 47th Annual Meeting and Exposition, American Society of Hematology; December 2005; Atlanta GA, Poster [68].
  6. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Gordon H. Guyatt, Elie A. Akl, Mark Crowther, Holger J. Schünemann, David D. Gutterman, Sandra Zelman Lewis. February 2012
  7. Goldhaber SZ. Deep vein thrombosis: advancing awareness to protect patient lives. White paper. American Public Health Association; Public Health Leadership Conference: Washington, DC: February 26, 2003.
  8. Spencer FA, Lessard D, Emery C et.al. Venous Thromboembolism in the Outpatient Setting. Arch Intern Med/Vol (NO. 14), July 23, 2007.
  9. Murin et al. Thromb Haemost. Comparison of the Outcomes after Hospitalization for Deep Venous Thrombosis or Pulmonary Embolism. 2002; 88:407-14.
  10.  Gerotziafas GT, Samama MM. Prophylaxis of venous thromboembolism medical patients. CurrOpin PulmMed. 2004; 10:356-365.
  11.  The National Alliance for Thrombosis and Thrombophila. Postthrombotic Syndrome (Venous Stress Disorder): An Indepth Guide for patients and health care providers. Available at http://www.stoptheclot.org/natt_publications/post_thrombotic_syndrome.pdf (Accessed September 16, 2009).
  12.  About.com. How the Blood Clots; How to Prevent Abnormal Clotting. Available at http://heartdisease.about.com/cs/heartattacks/a/clotting_3.htm (Accessed September 15, 2009).
  13.  Mayo Clinic. Complications. Available at http://www.mayoclinic.com/health/deep-vein-thrombosis/DS01005/DSECTION=6 [Accessed September 8, 2009].
  14.  Vascular Disease Foundation. Frequently Asked Questions. Available at http://www.vdf.org/diseaseinfo/dvt/faqs.php [Accessed September 15,2009].
  15.  Clot Care Online Resource. What is the d-Dimer test? Available at: http://www.clotcare.com/clotcare/faq_ddimertest.aspx [Accessed September 15,2009].
  16.  Heit JA. Venous thromboembolism epidemiology. Semin Thromb Hemost. 2002;28(suppl 2):3-13.
  17.  DeSancho et al. Bleeding and Thrombotic Complications in Critically Ill Patients with Cancer. Critical Care Clinics. 2001: 17:599-622.
  18.  Maiocco, Gina. DVT Prevention for the Obese Patient: Evidence-based Nurisng Interventions. Bariatric Nursing and Surgical Patient Care, Vol. 3, No. 4 2008: 279-284.
  19.  Zoller B, Hillarp A, Berntorp E, Dahlback B. Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis. Annual Review of Medicine 1997; 48: 45-58.
  20.  Vacular Disease Foundation. Focus on Blood Clots. Venous Thromboembolism(VTE): What you need to know about risk factors, symptoms and treatment . [Accessed September 28, 2009].
  21.  Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJM III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809-815.
  22.  Agency for Healthcare Research and Quality (AHRQ). Appendix A: Talking Points to Attract Administration Support for Venous Thromboembolism Prevention Programs. Hospitalized patients are at high risk for venous thromboembolism (VTE). Available at http://www.ahrq.gov/qual/vtguide/vtguideapa.htm [Accessed September 8, 2009].
  23.  Centers for Disease Control and Prevention (CDC). Are You At Risk for Deep Vein Thrombosis? Available at http://www.cdc.gov/Features/Thrombosis (accessed September 8, 2009).
  24.  U.S. Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. High Blood Cholesterol: What You Need To Know. Revised June 2005. Available at http://www.nhlbi.nih.gov/health/public/heart/chol/wyntk.htm (Accessed September 15, 2009).
  25.  American Heart Association (AHA). Fiber AHA Recommendation. Available at http://www.americanheart.org/presenter.jhtml?identifier=4574 (accessed September 15, 2009).
  26.  American Heart Association (AHA). Fiber AHA Recommendation. Available at http://www.americanheart.org/presenter.jhtml?identifier=4632 (accessed September 15, 2009).
  27.  Lee, A.Y., et al. (2003) “Low-Molecular-Weight Heparin vs. Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer: Randomized Comparison of Low-Molecular-Weight Heparin vs. Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer.” New England Journal of Medicine 349:146-153.
  28.  Lynman, Gary H. et.al. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer. J Clin Oncol 25:5490-5505.
  29.  American Heart Association. Common Cardiovascular Diseases. Available at http://www.americanheart.org/ presenter.jhtml?identifier=2873 (Accessed September 8, 2009).
  30.  American Heart Association. Risk Factors and Coronary Artery Disease. Available at http://www.americanheart.org/ presenter.jhtml?identifier=4726 (Accessed September 8, 2009).
  31.  Office of the Surgeon General. The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. Available at http://sg.cit.nih.gov/topics/deepvein/calltoaction/call-to-action-on-dvt-2008.pdf [Accessed September 2, 2009].
  32.  Rizkallah J, Man SF, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest. 2009 Mar;135(3):786-93.
  33.  Agency for Healthcare Research and Quality (AHRQ). National Healthcare Disparities Report, 2003 Summary. Available at http://www.ahrq.gov/qual/nhdr03/nhdrsum03.htm . [Accessed September 8, 2009].
  34.  Galson, Steven K. Public Health Reports. Surgeon General Perspectives. July-August 2008; Vol. 123.
  35.  Emerging Strategies in the Prevention of Venous Thromboembolismin Hospitalized Medical Patients Alex c.Spyropoulos CHEST 2005
  36.  ENDORSE study:Venous thromboembolism risk and prophylaxis in the acute hospital care setting:a multinational cross-sectional study Alexander T. Cohen, Victor t. Tapson, Jean-Francois Bergman, Samuel Z Goldhaber, Ajay Kakkar,Bruno Deslands, Wei Huang, Maksim Zayaruzny, Leigh Emery, Frederick A Anderson Jr,   The Lancet 2008
  37.  U.S. Department of Health and Human Services. The Surgeon General’s call to action to prevent deep vein thrombosis and pulmonary embolism: 2008. Office of the Surgeon General website. http://www.surgeongeneral.gov/topics/deepvein/calltoaction/call-to-action-on-dvt-2008.pdf . September 15, 2008. Accessed October 20, 2008.

  38.  Alikhan R, Cohen AT, Combe S, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis. 2003;14(4):341-346.

  39.  Samama MM, Cohen AT, Darmon J-Y, et al; Prophylaxis in Medical Patients with Enoxaparin Study Group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341(11):793-800.

  40.  Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am. 1999;81-A(7):932-940.

  41.  Bergqvist D, Benoni G, Björgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996;335(10):696-700.

  42.  ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg. 1997;84(8):1099-1103.

  43.  Hylek EM, Regan S, Henault LE, et al. Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. Arch Intern Med. 2003;163(5):621-627.
    Gerotziafas GT, Samama MM. Prophylaxis of venous thromboembolism in medical patients.Curr Opin Pulm Med. 2004;10(5):356-365.

  44.  Heit JA, Cohen AT, Anderson FA; VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Poster 68. Presented at: 47th Annual Meeting and Exposition of the American Society of Hematology; December 10-13, 2005; Atlanta, GA.
    Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost. 2002;88(3):407-414.
    Amin A, Stemkowski S, Lin J, Yang G. Thromboprophylaxis rates in US medical centers: success or failure? J Thromb Haemost. 2007;5(8):1610-1616.

  45.  נתוני החברה הישראלית לקרישת הדם